Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H22FN3O2S |
Molecular Weight | 411.492 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC=C(C=C1)C(=O)C2CCN(CCN3C(=S)NC4=C(C=CC=C4)C3=O)CC2
InChI
InChIKey=SMYALUSCZJXWHG-UHFFFAOYSA-N
InChI=1S/C22H22FN3O2S/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29)
Molecular Formula | C22H22FN3O2S |
Molecular Weight | 411.492 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/21996132
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21996132
Altanserin is a potent and selective 5-HT2A receptor antagonist. Serotonin (5-HT) system functioning have been proposed for a variety of psychiatric disorders, but a direct method quantitatively assessing 5-HT release capacity in the living human brain is still lacking. It was suggested that the combination of a dexfenfluramine-induced 5-HT release and subsequent assessment of 5-HT(2A) receptor availability with [(18)F]altanserin by positron emission tomography (PET) was suitable to measure cortical 5-HT release capacity in the human brain. Besides human neuroimaging studies altanserin has also been used in the study of rats.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P28223 Gene ID: 3356.0 Gene Symbol: HTR2A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15006678 |
0.3 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Disturbance of serotonin 5HT2 receptors in remitted patients suffering from hereditary depressive disorder. | 2001 Aug |
|
Distribution of 5HT2A receptors in the human brain: comparison of data in vivo and post mortem. | 2002 |
|
Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness. | 2004 Jun |
|
Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia. | 2005 Dec |
|
Acute S-ketamine application does not alter cerebral [18F]altanserin binding: a pilot PET study in humans. | 2007 |
|
Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome. | 2007 Apr |
|
The 5-HT2A receptor binding pattern in the human brain is strongly genetically determined. | 2008 Apr 15 |
|
5-HT2A receptor density is decreased in the at-risk mental state. | 2008 Jan |
|
Assessment of the Potential Role of Tryptophan as the Precursor of Serotonin and Melatonin for the Aged Sleep-wake Cycle and Immune Function: Streptopelia Risoria as a Model. | 2009 |
|
A PET [18F]altanserin study of 5-HT2A receptor binding in the human brain and responses to painful heat stimulation. | 2009 Feb 1 |
|
Gender and the use of hormonal contraception in women are not associated with cerebral cortical 5-HT 2A receptor binding. | 2009 Oct 6 |
|
Regional distribution and behavioral correlates of 5-HT(2A) receptors in Alzheimer's disease with [(18)F]deuteroaltanserin and PET. | 2009 Sep 30 |
|
A nonlinear relationship between cerebral serotonin transporter and 5-HT(2A) receptor binding: an in vivo molecular imaging study in humans. | 2010 Mar 3 |
|
Cerebral 5-HT2A receptor and serotonin transporter binding in humans are not affected by the val66met BDNF polymorphism status or blood BDNF levels. | 2010 Nov |
|
Evaluation of [(11)C]metergoline as a PET radiotracer for 5HTR in nonhuman primates. | 2010 Nov 15 |
|
Structural combination of established 5-HT(2A) receptor ligands: new aspects of the binding mode. | 2010 Oct |
|
Endogenous plasma estradiol in healthy men is positively correlated with cerebral cortical serotonin 2A receptor binding. | 2010 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21996132
Thirteen healthy male subjects received placebo and single oral doses of 40 mg (n = 6) or 60 mg (n = 7) of the potent 5-HT releaser dexfenfluramine separated by an interval of 14 days. Three further subjects received placebo on both days. Two hours after placebo/drug administration, 250 MBq of the 5-HT(2A) receptor selective PET-radiotracer [(18)F]altanserin was administered intravenously as a 30s bolus.
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:31:32 GMT 2023
by
admin
on
Sat Dec 16 16:31:32 GMT 2023
|
Record UNII |
5015H744JQ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66885
Created by
admin on Sat Dec 16 16:31:32 GMT 2023 , Edited by admin on Sat Dec 16 16:31:32 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C77258
Created by
admin on Sat Dec 16 16:31:32 GMT 2023 , Edited by admin on Sat Dec 16 16:31:32 GMT 2023
|
PRIMARY | |||
|
SUB05375MIG
Created by
admin on Sat Dec 16 16:31:32 GMT 2023 , Edited by admin on Sat Dec 16 16:31:32 GMT 2023
|
PRIMARY | |||
|
C071983
Created by
admin on Sat Dec 16 16:31:32 GMT 2023 , Edited by admin on Sat Dec 16 16:31:32 GMT 2023
|
PRIMARY | |||
|
CHEMBL62919
Created by
admin on Sat Dec 16 16:31:32 GMT 2023 , Edited by admin on Sat Dec 16 16:31:32 GMT 2023
|
PRIMARY | |||
|
5395
Created by
admin on Sat Dec 16 16:31:32 GMT 2023 , Edited by admin on Sat Dec 16 16:31:32 GMT 2023
|
PRIMARY | |||
|
278-422-1
Created by
admin on Sat Dec 16 16:31:32 GMT 2023 , Edited by admin on Sat Dec 16 16:31:32 GMT 2023
|
PRIMARY | |||
|
5015H744JQ
Created by
admin on Sat Dec 16 16:31:32 GMT 2023 , Edited by admin on Sat Dec 16 16:31:32 GMT 2023
|
PRIMARY | |||
|
76330-71-7
Created by
admin on Sat Dec 16 16:31:32 GMT 2023 , Edited by admin on Sat Dec 16 16:31:32 GMT 2023
|
PRIMARY | |||
|
3033677
Created by
admin on Sat Dec 16 16:31:32 GMT 2023 , Edited by admin on Sat Dec 16 16:31:32 GMT 2023
|
PRIMARY | |||
|
100000087474
Created by
admin on Sat Dec 16 16:31:32 GMT 2023 , Edited by admin on Sat Dec 16 16:31:32 GMT 2023
|
PRIMARY | |||
|
DTXSID5043891
Created by
admin on Sat Dec 16 16:31:32 GMT 2023 , Edited by admin on Sat Dec 16 16:31:32 GMT 2023
|
PRIMARY | |||
|
ALTANSERIN
Created by
admin on Sat Dec 16 16:31:32 GMT 2023 , Edited by admin on Sat Dec 16 16:31:32 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
LABELED -> NON-LABELED | |||
|
LABELED -> NON-LABELED | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |